# Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

> **NCT05876065** · NA · RECRUITING · sponsor: **Wenjin Yin** · enrollment: 86 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** XC
- **DRUG:** TPC

## Key facts

- **NCT ID:** NCT05876065
- **Lead sponsor:** Wenjin Yin
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-06
- **Final completion:** 2027-02
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876065, "Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05876065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*